03 Jan Iradimed Corp: Making MRI Procedures Safer and Easier
Iradimed Corporation (NASDAQ: IRMD) develops, manufactures, markets, and distributes MRI-compatible medical devices and accessories, disposables, and related services.
Iradimed Corporation (NASDAQ: IRMD)
Market Cap: $596.12M; Current Share Price: 47.47 USD
Data by YCharts
The Company and its Products
Iradimed is the only known provider of a non-magnetic intravenous (IV) infusion pump system specifically designed to be safe during MRI procedures. The Company is the first to develop an infusion delivery system that eliminates many dangers and problems during MRI procedures.
Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system.
Image Source: Company
Iradimed’s patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures.
Iradimed’s 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room.
The IRADIMED 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units.
Image Source: Company
The Company sells products primarily to hospitals and acute care facilities in the United States and internationally. It currently employs a direct sales strategy in the United States. As of December 31, 2022, Iradimed’s direct sales force consisted of 25 field sales representatives, supported by three regional sales directors and supplemented by five clinical application specialists. Internationally, the Company markets products in approximately 80 countries through independent distributors.
As of December 31, 2022, Iradimed had sold approximately 6,582 MRI-compatible IV infusion pump systems and approximately 1,596 of 3880 MRI-compatible patient vital signs monitoring systems.
The Company generates revenue from the sale of MRI-compatible medical devices and related accessories, extended warranty agreements, services related to maintaining the products, and the sale of disposable products used with the devices.
We will discuss the critical rationale for covering the Company.
- Global Market Opportunity
MRI is a widely used, non-invasive medical imaging technique to visualize vital organs and bodily function and to identify blockages, abnormalities, and growths. MRI is generally considered safer than other scanning techniques that expose the body to radiation. This is particularly true for children. As such, practitioners at hospitals and other medical facilities have been increasingly developing and using MRI for new procedures. These procedures include cardiac stress testing, intraoperative MRI, and neurology MRI techniques.
Iradimed’s MRI-compatible products offer a way to continuously deliver essential IV fluids safely and accurately while also monitoring the vital signs of critically ill or sedated patients, thereby allowing the expanded use of MRI procedures, better or quicker diagnosis, and treatments that may lead to shorter hospital stays resulting in lower health care costs. Moreover, the Company’s MRidium MRI-compatible IV infusion pump system is the first and only product to provide an easy-to-operate, non-magnetic, safe, and RF-quiet solution.
Currently, there is the potential for the sale of approximately 27,350 MRI-compatible IV infusion pump systems based on the number of MRI scanners installed globally in acute care facilities of sufficient sophistication as to be considered supporting favorable market conditions for utilization of Iradimed’s MRI-compatible IV infusion pump system.
Image Source: Company
Additionally, based on historical sales data and customer purchasing behaviors, through the use of Iradimed’s direct U.S. sales team, there is potential for sales of MRI-compatible IV infusion pump systems within critical care departments of U.S. hospitals. Based on an estimate of the number of critical care departments in the U.S., there is the potential to sell an additional 10,450 MRI-compatible IV infusion pump systems. The combined sales based on the number of targeted MRI scanners and critical care departments of U.S. hospitals result in a global target market of approximately 37,800 MRI-compatible IV infusion pump systems.
There is an enormous opportunity for Iradimed since its products have no direct competition. There is also an opportunity for pumps as workflow solutions lead to multiple customer device orders. The Company’s next-generation pump is planned for late 2024 to early 2025. Hence, there will also be significant replacement opportunities for the new pumps because a large percentage of the installed base will be nearing the end of life.
Image Source: Company
- Sound Commercial Strategy
MRI-compatible IV infusion pump market continues to have growth potential given the low rate of market penetration, and Iradimed aims to drive increased awareness, adoption, and utilization of its MRI-compatible products by
- Continued development of MRI-focused U.S. direct sales force and international sales efforts: Since there is no current direct competitor for an MRI-compatible IV infusion pump, Iradimed’s focus is on expanding the market through better education on the advantages to patients, clinicians, and hospitals of the infusion pump solution and the shortcomings of current work around practices. Additionally, with the 3880 Monitor, the Company focuses on educating customers on the total workflow benefits the devices offer and how the devices increase the efficiency of MRI scanners via patient throughput.
- Supporting commercial efforts with evidence-based information: Iradimed’s sales team focuses on educating customers on the safety and efficiency benefits of using its MRI-compatible products. To assist in the education process, the Company has developed materials documenting the risks and additional costs associated with using a workaround solution to running long lines from conventional IV pumps outside the MRI scanner room.
Image Source: Company
- Providing best-in-class customer service and user experience: Once customers purchase Iradimed’s products, they receive first-class clinical education and support to encourage usage of these products. The Company devotes a significant amount of time and training to ensure this educational experience is successful. This training is performed most commonly by the sales staff and is augmented by the clinical application specialists.
- Financial Performance
The Company’s growth roadmap envisions two times FY22 revenue within three years through the measures shown below:
Image Source: Company
For Q3 FY23, the Company reported over 23% YoY revenue growth to $16.5 million compared to $13.4 million for Q3 FY22. Net income was $5.1 million, or $0.40 per diluted share, compared to $3.4 million, or $0.27 for Q3 FY22.
Image Source: Company
For FY22, the Company reported revenue of $53.3 million compared to $41.8 million for the same period in FY21. Net income was $12.8 million, or $1.02 per diluted share, compared to $9.3 million, or $0.74 per diluted share, for FY21.
Image Source: Company
For Q4 FY23, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38, and non-GAAP diluted earnings per share of $0.38 to $0.41.
For FY23 financial guidance, the Company expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37, and non-GAAP diluted earnings per share of $1.48 to $1.51.
As can be seen from the above graph, Iradimed has shown a trend of significant revenue growth over the last three years, accompanied by sky-high gross margin. This pattern seems to continue, making the Company an exciting watch.
Risks
Iradimed seems to have a promising future; however, the Company is exposed to certain risks. Firstly, the medical products industry is characterized by intense competition and extensive research and development. The market for medical products is subject to rapid change due to an increasingly competitive, cost-conscious environment and government programs intended to reduce the cost of medical care. Thus, Iradimed may be unable to cope with innovations introduced by other companies.
Secondly, changes in government regulations could force Iradimed to modify how it develops, manufactures, markets, and prices products. The Company may also suffer due to failure to obtain, or experience significant delays in obtaining, FDA clearances or other necessary approvals to commercially distribute new products.
Conclusion
Iradimed’s revenues have grown exponentially over the last three years. The Company’s growth streak seems to continue due to expected demand for its innovative, one-of-a-kind product. However, Iradimed is subject to risks such as changes in government regulations and medical technology change. Hence, investors should proceed with caution.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Click here to please visit our detailed disclosure
Reference:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1325618/000110465923028003/irmd-20221231x10k.htm
https://www.sec.gov/ix?doc=/Archives/edgar/data/1325618/000155837023017594/irmd-20230930x10q.htm
https://www.iradimed.com/news/iradimed-corporation-announces-third-quarter-2023-financial-results
Sorry, the comment form is closed at this time.